108 related articles for article (PubMed ID: 20196680)
1. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.
Sun C; Meng F; Li Y; Jin Q; Li H; Li F
Artif Cells Blood Substit Immobil Biotechnol; 2010 Apr; 38(2):99-102. PubMed ID: 20196680
[TBL] [Abstract][Full Text] [Related]
2. Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum.
Guo CY; Li ZY; Xu MQ; Yuan JM
J Immunol Methods; 2005 Aug; 303(1-2):142-7. PubMed ID: 16040047
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
[TBL] [Abstract][Full Text] [Related]
4. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.
Psaridi-Linardaki L; Trakas N; Mamalaki A; Tzartos SJ
J Neuroimmunol; 2005 Feb; 159(1-2):183-91. PubMed ID: 15652418
[TBL] [Abstract][Full Text] [Related]
5. A sensitive non-isotopic assay for acetylcholine receptor autoantibodies.
Hewer R; Matthews I; Chen S; McGrath V; Evans M; Roberts E; Nute S; Sanders J; Furmaniak J; Smith BR
Clin Chim Acta; 2006 Feb; 364(1-2):159-66. PubMed ID: 16051208
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries.
Rey E; Zeidel M; Rhine C; Tami J; Krolick K; Fischbach M; Sanz I
Clin Immunol; 2000 Sep; 96(3):269-79. PubMed ID: 10964546
[TBL] [Abstract][Full Text] [Related]
7. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
Takamori M; Maruta T
Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
[TBL] [Abstract][Full Text] [Related]
8. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
9. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
Tzartos SJ; Sophianos D; Efthimiadis A
J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
[TBL] [Abstract][Full Text] [Related]
10. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
Pták J
Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci.
Protopapadakis E; Kokla A; Tzartos SJ; Mamalaki A
Eur J Immunol; 2005 Jun; 35(6):1960-8. PubMed ID: 15915538
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
Kawanami S; Tsuji R; Oda K
Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
[TBL] [Abstract][Full Text] [Related]
13. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
[TBL] [Abstract][Full Text] [Related]
14. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
[TBL] [Abstract][Full Text] [Related]
15. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.
Takamori M; Ide Y
Transfus Sci; 1996 Sep; 17(3):445-53. PubMed ID: 10163553
[TBL] [Abstract][Full Text] [Related]
16. Adsorption column for myasthenia gravis treatment: Medisorba MG-50.
Nakaji S; Hayashi N
Ther Apher Dial; 2003 Feb; 7(1):78-84. PubMed ID: 12921120
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains.
Zisimopoulou P; Lagoumintzis G; Poulas K; Tzartos SJ
J Neuroimmunol; 2008 Aug; 200(1-2):133-41. PubMed ID: 18603305
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific apheresis of autoantibodies in myasthenia gravis.
Lazaridis K; Zisimopoulou P; Lagoumintzis G; Skriapa L; Trakas N; Evangelakou P; Kanelopoulos I; Grapsa E; Poulas K; Tzartos S
Ann N Y Acad Sci; 2012 Dec; 1275():7-12. PubMed ID: 23278571
[TBL] [Abstract][Full Text] [Related]
19. In-line affinity chromatographic removal of specific antibody from rabbits with experimental myasthenia gravis as a prelude to immunotherapy.
Hinman CL; Stevens-Truss R
Immunopharmacol Immunotoxicol; 1998 May; 20(2):233-49. PubMed ID: 9653670
[TBL] [Abstract][Full Text] [Related]
20. [Antibody against synthetic peptide corresponding to alpha-subunit residues 128-142 of nicotinic acetylcholine receptor (AChR): the significance in myasthenia gravis (MG)].
Shibuya N; Kanazawa H; Uyemura K
Rinsho Shinkeigaku; 1988 Mar; 28(3):315-9. PubMed ID: 3402139
[No Abstract] [Full Text] [Related]
[Next] [New Search]
